Screening and management of diabetic microvascular complications in older adults

Geriatrics and Aging

Volumn 7, Issue 1, 2004, Pages 22-30

  Parikh, Amish ^a   Fantus, I George ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diabetes mellitus; Management; Nephropathy; Neuropathy; Retinopathy; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; HEMOGLOBIN A1C; IMIPRAMINE; LAMOTRIGINE; NARCOTIC AGENT; NITRATE; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; PLACEBO; SILDENAFIL;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; ERECTILE DYSFUNCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERKALEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MEDICAL SOCIETY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; SCREENING;

EID: 1042292054     PISSN: 14888408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Fong DS, Aiello L, Gardner TW, et al; American Diabetes Association. Diabetic retinopathy. Diabetes Care 2003;26 Suppl 1:S99-S102.
2. Chew EY, Ferris FL 3rd, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003;110:1683-9.
3. Whitmore WG. Eye disease in a geriatric nursing home population. Ophthalmology 1989;96:393-8.
4. Mitchell P, Hayes P, Wang JJ. Visual impairment in nursing home residents: the Blue Mountains Eye Study. Med J Aust 1997;166:73-6.
5. Hirvela H, Laatikainen L. Diabetic retinopathy in people aged 70 years or older. The Oulu Eye Study. Br J Ophthalmol 1997;81:214-7.
6. Squirrell DM, Talbot JF. Screening for diabetic retinopathy. J R Soc Med 2003;96:273-6.
7. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-9.
8. Arun CS, Ngugi N, Lovelock L, et al. Effectiveness of screening in preventing blindness due to diabetic retinopathy. Diabet Med 2003;20:186-90.
9. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risks factors. Arch Ophthalmol 1998;116:297-303.
10. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98(5 Suppl):766-85.
11. Kohner EM, Stratton IM, Aldington SJ, et al. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. Diabetologia 1999;42:1107-12.
12. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:997-86.
13. The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995;113:36-51.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
15. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
16. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-63.
17. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991;98(5 Suppl):757-65.
18. Chew EY, Klein ML, Ferns FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment of Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
19. Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56:1-11.
20. Genest J, Frohlich J, Fodor G, et al. (the Working Group on Hypercholesterolemia and Other Dyslipidemias). Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. Appendix to CMAJ 2003;168:921-4 [on-line publication only].
21. Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Am J Kidney Dis 2003;41(3 Suppl 1):S22-5.
22. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-93.
23. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45-66.
24. Adler AI, Stevens RJ, Manley SE, et al; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.
25. Meinhardt U, Ammann RA, Fluck C, et al. Microabuminuria in diabetes mellitus: efficacy of a new screening method in comparison with timed overnight urine collection. J Diabetes Complications 2003;17:254-7.
26. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
27. Lasaridis AN, Sarafidis PA. Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? Am J Hypertens 2003;16:689-97.
28. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6.
29. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
30. Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002;15:123S-128S.
31. Eberhard R, Dikow R. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes. Ann Med 2002;34:507-13.
32. Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74.
33. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80.
34. Arauz-Pacheco C, Parrott MA, Raskin P; American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26 Suppl 1:S80-2.
35. UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2003;321:412-9.
36. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
37. Jenkins AJ, Lyons TJ, Zheng D, et al; DCCT/EDIC Research Group. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003;64:817-28.
38. Bruno G, Merletti F, Biggeri A, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2003;26:2150-5.
39. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care 1997;20:836-43.
40. Perkins BA, Olaleye D, Zinman B, et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250-6.
41. Calle-Pascual AL, Duran A, Benedi A, et al. A preventative foot care programme for people with diabetes with different stages of neuropathy. Diabetes Res Clin Pract 2002;57:111-7.
42. Ametov AS, Barinov A, Dyck PJ, et al; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26:770-6.
43. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 2003;20:88-98.
44. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. J Urol 2003;170:S35-8.
45. Goldstein I, Young JM, Fischer J, et al; Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
46. Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2003;26:279-84.
47. Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002;25:2159-64.
48. Maser RE, Mitchell BD, Vinik AI, et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895-901.
49. Whang W, Bigger JT Jr. Comparison of the prognostic value of RR-interval variability after acute myocardial infarction in patients with versus those without diabetes mellitus. Am J Cardiol 2003;92:247-51.
50. Dawson KG, Gomes D, Gerstein H, et al. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002;25:1303-7.
51. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
52. Brown AF, Mangione CM, Saliba D, et al; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51(5 Suppl Guidelines):S265-80.
53. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ 1998;159 Suppl 8:S1-29.
54. Bo S, Repetti E, Pagano G, et al. Type 2 diabetes with onset in the elderly is not a benign disease. Diabet Med 2002;19:792-4.